Why Attend Antigen-Specific Immune Tolerance Drug Development Summit?
With excitement and opportunity for those who act now and successfully overcome the scientific, product development, regulatory and commercialization challenges associated with antigen-specific immune tolerance therapies – Join the 1st Antigen-Specific Immune Tolerance Drug Development Summit 2018 to:
|Revisit and widen your understanding of underlying causes of autoimmunity from world-class experts such as Immune Tolerance Network, JDRF, NIH and Harvard University.|
|Find out about the most innovative therapeutic approaches that target immune tolerance pathways from leading companies such as Takeda, Pfizer, Novartis & Eli Lilly.|
|Through real world case studies from the likes of FDA, Tolerion, Nektar Therapeutics, AnTolRx, Selecta Biosciences & Topas Therapeutics maximize your success rates to translate ground breaking science into a novel class of therapies to treat autoimmunity.|
|Debate, challenge and cut through the hurdles associated with successful translation from pre-clinic to clinic and how to design robust human trials for effective antigen-specific immune tolerance therapies.|
|Find out what is the future regulatory and commercialization directions of antigen-specific immune tolerance therapies from the key decision makers within FDA, big pharma and leading biotech companies.|